A bispecific monoclonal antibody ( BsMAb , BsAb ) is an artificial protein that can simultaneously bind to two different types of antigen or two different epitopes on the same antigen. Naturally occurring antibodies typically only target one antigen. BsAbs can be manufactured in several st...
Bispecific antibodies (BsAbs) have two distinct binding domains that can bind to two antigens or two epitopes (an antigen part) of the same antigen simultaneously. Over the past two decades, BsAb development has been revolutionized due to genetic engineering approaches that enable a wide variety of molecular structures that offer different advantages and disadvantages. BsAbs are next generation monoclonal antibodies (mAbs). Typical mAbs target one epitope.1 FDA approved the first mAb, Orthoclone...
AbbVie's new bispecific antibody (IgG1) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), 'EPKINLY (epcoritamab)', is set to
Platform Technology ; Bispecific Antibody
to bispecific antibody stability and the reversal of self-associated aggregates Nattha Ingavat Nuruljannah Dzulkiflie Wei Zhang Bioresources and Bioprocessing (2024) CD28 co-stimulation...
Medical professionals have expressed great expectations for Epkinly (epcoritamab), a third-line treatment for diffuse large B-cell lymphoma (DLBCL) recently introduced in Korea. AbbVie Korea held a press conference last Wednesday to celebrate the approval of Epkinly. It is a bispecific antibody that targets CD20 and CD3 approved by the Ministry of Food and Drug Safety (MFDS) on June 20 for treating adult patients 18 and older with relapsed or refractory DLBCL after two or more systemic therapies...
Significance : Human models that recapitulate the cellular diversity, 3 dimensional architecture, and physiological function of native tissues are needed to evaluate emerging cancer immuno-therapeutics, such as T cell bispecific antibodies (TCBs). One target of substantial interest is Wilms Tumor 1 (WT1), a highly validated tumor antigen expressed in multiple leukemias and solid tumors as well as podocytes present in human kidneys. To assess their “off-tumor, on-target” effects, we created an immune-infiltrated, vascularized kidney organoid ...
Patent Title : Bispecific proteins and methods for preparing same, Patent No. WO2018016881A1
The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from relatively sma...
The clinical trial for 'BH3120', a next-generation immunotherapy using the bispecific antibody platform technology 'PENTAMBODY' independen